The effects of chronic usage of enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients

References (1)

1. Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, et al. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-indu- ced nephropathy. Int Urol Nephrol 2008; 40: 749-55. [CrossRef] 2. Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H. Impact of renin-angi- otensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-Versus-Diuresis (DVD) trial. Nephrol Dial Transplant 2010; 25: 759-64. [CrossRef] 3. Umruddin Z, Moe K, Superdock K. ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy. J Nephrol 2012; 25: 776-81. [CrossRef] 4. The ad-hoc working group of ERBP: Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, et al. A European Renal Best Practice (ERBP) posi- tion statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 2012; 27: 4263-72. 5. Özcan EE, Güneri S, Akdeniz B, Akyıldız IZ, Şenaslan O, Barış N, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radio- contrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedu- res. A single-center prospective controlled trial. Am Heart J 2007; 154: 539-44. [CrossRef] 6. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast induced nephropathy after coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-9. [CrossRef]